The next controllable payload class for targeted oncology.
A first-in-class, light-activatable intracellular payload designed to add an independent spatial control layer to antibody- and peptide-based cancer therapies.
Molecular targeting decides where. Light decides when.
GenLumina is building a modular payload platform for targeted cancer therapies. The platform combines molecular targeting with local light activation, creating two independent layers of control and a route to multiple partner-specific programmes.
European science, early conviction and a platform-scale opportunity.
Sofinnova Capital invests as a founding or lead investor in early-stage European biopharma and medtech companies with strong intellectual property and the potential to transform patient outcomes.
Novel payload thesis
GenLumina addresses a challenge Sofinnova has already recognised: differentiated payloads can improve therapeutic index and create platform value across targeted oncology programmes.
Testable value inflection
A disciplined evidence plan can test targeting, biodistribution, safety, efficacy and manufacturability before larger clinical capital is committed.
Strong platform IP
The protected light-controlled payload can be evaluated with antibodies, peptides and other ligands across separately licensed partner programmes.
European company building
Sofinnova's Paris and London presence fits GenLumina's location at Leiden Bio Science Park and its ambition to build a globally relevant European oncology company.
A proven path from one testable question to platform value.
Myricx is not presented as a direct technological comparable. Its development illustrates how Sofinnova combines early scientific conviction, disciplined experiments, strategic adaptation and long-term financing support.
Define the question
Myricx's seed programme was structured around a decisive issue: could the science deliver a therapeutic index suitable for clinical development?
Let data decide
Focused bridge capital tested whether the molecules could work as ADC payloads before the company committed to a broader platform strategy.
Build the platform
The resulting data supported a transition from a single-asset story to a differentiated payload platform with broad solid-tumour potential.
Scale the value
Sofinnova remained involved from seed through a major Series A and the subsequent agreement for acquisition by Novartis.
Two layers of precision. One controllable payload.
Molecular targeting determines where the payload goes. Light adds an independent spatial switch that controls where cytotoxic activity is activated.
Molecular targeting
Antibody or peptide directs the payload to tumour cells.
Intracellular delivery
Payload enters and localises within target cells.
Spatial activation
Local light activates the intracellular payload.
Selective killing
Activated payload drives tumour-cell cytotoxicity.
Targeting has advanced. Payload control has not.
Targeted therapies still need to balance potency, systemic exposure and tolerability. GenLumina adds a second, independent gate: the targeting molecule directs the construct, while local light controls where the intracellular payload becomes active.
- In-vitro proof-of-concept in targeted and conjugated approaches
- Activity shown in breast and colorectal cancer models
- Initial in-vivo biodistribution and safety observations within the preclinical programme
- Targeted in-vivo efficacy and dose optimisation
- Expanded biodistribution, safety and therapeutic-window data
- Reproducible conjugation, formulation and manufacturability package
Built to partner broadly.
Modular conjugation to antibodies, peptides and other targeting ligands — designed to work with existing biology and image-guided workflows.
Finance the evidence that unlocks partner programmes.
GenLumina is exploring a staged strategic equity investment toward CTA/IND-enabling preparation, but only where a specialist lead investor contributes more than capital: oncology expertise, hands-on company building, syndication capacity and access to pharmaceutical partners.
Complete the next in-vivo and product-readiness milestones.
Combine specialist private capital with grants, research funding and partner-funded PoCs.
Create defined routes to option-to-license, co-development and programme licences.
Help build the next differentiated payload platform.
We invite Sofinnova Capital to explore a lead investment in GenLumina and to assess how its oncology, payload and European company-building experience could accelerate the path from focused preclinical validation to pharmaceutical partnering.